Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 7/20 | 0.46 |
| ▸ | CTSS | P25774 | 6/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | PPARA | Q07869 | 7/20 | 0.41 |
| ▸ | PPARG | P37231 | 6/20 | 0.41 |
| ▸ | CTSL | P07711 | 1/20 | 0.41 |
| ▸ | CTSB | P07858 | 1/20 | 0.41 |
| ▸ | ACE | P12821 | 1/20 | 0.41 |
| ▸ | PPARD | Q03181 | 2/20 | 0.40 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA7 | P43166 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.39 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL523768 | 1.00 | CTSK (0.46) | CTSKCTSSCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL523769 | 1.00 | CTSK (0.46) | CTSKCTSSCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL25412196 | 0.87 | CYP1A2 (0.54) | CTSKCTSSCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL524452 | 0.87 | CYP1A2 (0.45) | CTSKCTSSCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL30615307 | 0.87 | CYP1A2 (0.54) | CTSKCTSSCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL524451 | 0.87 | CYP1A2 (0.45) | CTSKCTSSCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL1111203 | 0.87 | CYP1A2 (0.45) | CTSKCTSSCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL3044101 | 0.86 | CTSK (0.48) | CTSKCTSSCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL29165002 | 0.86 | CTSK (0.44) | CTSKCTSSCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL30888824 | 0.86 | CTSK (0.44) | CTSKCTSSCYP1A2CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023174810-A1 | A PROCESS FOR THE SYNTHESIS OF ( R)-2-(( TERT-BUTOXYCARBONYL)AMINO)-3-(DIETHOXYPHOSPHORYL)PROPANOIC ACID OR OF PHOSPHONATE DERIVATIVES THEREOF | IDORSIA PHARMACEUTICALS LTD (CH) | 2023-09-21 | — | — | WO | disclosed |
| US-8518912-B2 | Phosphonic acid derivates and their use as P2Y12 receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2013-08-27 | — | — | US | disclosed |
| EP-2225253-B1 | PHOSPHONIC ACID DERIVATES AND THEIR USE AS P2Y12 RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2012-06-27 | — | — | EP | disclosed |
| US-8058263-B2 | Substituted 2-phenyl-pyridine derivatives | ACTELION PHARMACEUTICALS LTD (CH) | 2011-11-15 | — | — | US | disclosed |
| US-20110046089-A1 | SUBSTITUTED 2-PHENYL-PYRIDINE DERIVATIVES | VIATRIS ASIA PACIFIC PTE. LTD. (SG) | 2011-02-24 | — | — | US | disclosed |
| EP-2279191-A1 | SUBSTITUTED 2-PHENYL-PYRIDINE DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2011-02-02 | — | — | EP | disclosed |
| US-20100261678-A1 | PHOSPHONIC ACID DERIVATES AD THEIR USE AS P2Y12 RECEPTOR ANTAGONISTS | VIATRIS ASIA PACIFIC PTE. LTD. (SG) | 2010-10-14 | — | — | US | disclosed |
| EP-2225253-A1 | PHOSPHONIC ACID DERIVATES AND THEIR USE AS P2Y12 RECEPTOR ANTAGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2010-09-08 | — | — | EP | disclosed |
| WO-2009125366-A1 | SUBSTITUTED 2-PHENYL-PYRIDINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2009-10-15 | — | — | WO | disclosed |
| WO-2009069100-A1 | PHOSPHONIC ACID DERIVATES AND THEIR USE AS P2Y12 RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2009-06-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046089-A1 | SUBSTITUTED 2-PHENYL-PYRIDINE DERIVATIVES | P2RY12, P2RY13, P2RY11 | CTSK 4155/4885CTSS 4226/4885CYP1A2 555/4885 |
| US-20100261678-A1 | PHOSPHONIC ACID DERIVATES AD THEIR USE AS P2Y12 RECEPTOR ANTAGONISTS | P2RY12, P2RY13, P2RY11 | CTSK 4627/4885CTSS 4636/4885CYP1A2 2257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.